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BACKGROUND: Timely and efficient diagnostic workup of patients with head and neck cancer (HNC) is challenging. This observational 
study describes the implementation of an optimized multidisciplinary oncological diagnostic workup for patients with HNC and its im-
pact on diagnostic and treatment intervals, survival, costs, and patient satisfaction. METHODS: All patients with newly diagnosed HNC 
who underwent staging and treatment at the Radboud University Medical Center were included. Conventional workup (CW) in 2009 
was compared with the fast-track, multidisciplinary, integrated care program, that is, optimized workup (OW), as implemented in 2014. 
RESULTS: The study included 486 patients with HNC (218 with CW and 268 with OW). The time-to-treatment interval was significantly 
lower in the OW cohort than the CW cohort (21 vs 34 days; P < .0001). The 3-year overall survival rate was 12% higher after OW (72% 
in the CW cohort vs 84% in the OW cohort; P = .002). After correction for confounders, the 3-year risk of death remained significantly 
lower in the OW cohort (hazard ratio, 1.73; 95% confidence interval, 1.14-2.63; P = .010). Total diagnostic costs were comparable in the 
2 cohorts. The general satisfaction score, as measured with the Consumer Quality Index for Oncological Care, was significantly better 
in a matched OW group than the CW group (9.1 vs 8.5; P = .007). CONCLUSIONS: After the implementation of a fast-track, multidis-
ciplinary, integrated care program, the time-to-treatment interval was significantly reduced. Overall survival and patient satisfaction 
increased significantly, whereas costs did not change. This demonstrates the impact and improved quality of care achieved by effi-
ciently organizing the diagnostic phase of HNC management. Cancer 2020;126:3982-3990. ©2020 The Authors. Cancer published by 
Wiley Periodicals LLC on behalf of American Cancer Society This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly 
cited, the use is non-commercial and no modifications or adaptations are made. 
KEYWORDS: costs and cost analysis, delayed diagnosis, head and neck neoplasms, survival, time to treatment.
INTRODUCTION
Head and neck cancer (HNC) represents a relatively rare and heterogeneous group of tumors. These tumors are 
characterized by relatively fast growth in a functionally important and vulnerable anatomic site of the human body. 
Therefore, these tumors and their treatment often have a substantial impact on important functions such as breath-
ing, speech, and swallowing. Because of the complexity of diagnosis and treatment, a high degree of expertise and 
a multidisciplinary approach are required.1 For this reason, care for patients with HNC has to be centralized. As a 
result, the number of patients referred to these specialized centers is rising. This increase challenges the resources of 
these high-volume centers and may result in prolonged time-to-treatment intervals.2 The organization and integra-
tion of the various aspects of health care for complex diseases such as HNC requiring a multidisciplinary approach 
have become increasingly important.3 Simultaneously, the possibilities and complexity of diagnostic procedures and 
treatment options for patients with HNC are increasing, and this adds to the risk of increasing time-to-treatment in-
tervals.1,4,5 Time-to-treatment intervals are particularly important for patients with HNC because, as mentioned be-
fore, these tumors are relatively fast growing in an anatomically and functionally complex and delicate area. Although 
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the effect of time-to-treatment intervals on overall sur-
vival has been variably reported,6-9 recent large studies 
have demonstrated the unfavorable effects of long time-
to-treatment intervals.2,10 These 2 studies of large co-
horts of patients with HNC found that overall survival 
was significantly lower with larger intervals between di-
agnosis and treatment.2,10 In addition, studies compar-
ing diagnostic and radiotherapy planning imaging have 
demonstrated a higher tumor volume with the latter, 
which indicates tumor progression during the diagno-
sis-to-treatment interval.11,12 Increased tumor volume 
(and stage) may lead to more intensified therapy with 
increased associated morbidity and worse functional 
outcomes. This intensified treatment may compensate 
for the unfavorable effect of prolonged intervals on sur-
vival but comes at the price of additional costs and loss 
of function and quality of life.
In 2008, our Head and Neck Oncology Center 
(HNOC) started to redesign the diagnostic pathway 
for patients with HNC. We designed a fast-track, mul-
tidisciplinary, integrated care program and implemented 
numerous interventions over a period of 4 years (2010-
2013) to enhance quality and diminish delays. This study 
was aimed at assessing the impact of this fast-track, mul-
tidisciplinary, integrated care program on the quality of 
care and costs for patients with HNC.
MATERIALS AND METHODS
Design
To assess the impact of the fast-track, multidiscipli-
nary, integrated care program on the quality of care for 
patients with HNC, we performed a before and after 
study by using medical record searches and question-
naires. The study was approved by the medical ethics 
committee.
Study Population
All consecutive patients with suspected HNC diagnosed 
in 2009 and 2014 and treated with curative intent at the 
Radboud University Medical Center in Nijmegen were 
included. Primary epithelial tumors of the lip, oral cav-
ity, oropharynx, nasal vestibule, hypopharynx, larynx, 
and external auditory canal were included. In addition, 
all tumor types (except lymphomas) of the nasal cav-
ity, paranasal sinuses, nasopharynx, and salivary glands 
and metastases in the neck from an unknown primary 
tumor were included. Patients with previous treatment 
for their tumor elsewhere, previous HNC, or previous 
(chemo)radiotherapy in the head and neck area were 
excluded. We identified patients by using a prospective 
patient registry.
Diagnostic Process
All patients with proven cancer or a suspicion of can-
cer were guaranteed access to a first consultation within 
7 days of referral by the referring consultant.
All patients underwent a full oncological workup, 
including a medical history, a physical examination, 
and imaging, cytological, and/or histopathological ex-
aminations. Imaging consisted of computed tomogra-
phy (CT) and/or magnetic resonance imaging of the 
head and neck, ultrasonography with fine-needle aspi-
ration cytology (FNAC) of lymph nodes suspected for 
metastases (in all cases except Tis/1 glottic carcinoma), 
chest radiography or CT (chest CT in case of suspi-
cious low cervical lymph nodes or suspicious bilateral 
cervical lymph nodes), and positron emission tomog-
raphy (PET)–CT for unknown primary tumors. All 
cases were discussed at the multidisciplinary tumor 
board meeting, which included consultant head and 
neck surgeons (ear, nose, and throat and maxillofacial 
surgeons), consultant radiation oncologists, consultant 
medical oncologists, consultant pathologists, consul-
tant radiologists, consultant nuclear medicine physi-
cians, geriatricians, physician assistants, and oncology 
nurses. Tumors were classified according to the TNM 
Classification of Malignant Tumors (the sixth or sev-
enth edition depending on the date of diagnosis),13,14 
and a treatment recommendation was formulated.
The oncological workup for patients diagnosed in 
2009 (conventional workup [CW]) and 2014 (optimized 
workup [OW]) is summarized in more detail in Table 1 
and the supporting information.
Data Collection
The medical records of the patients were reviewed dur-
ing follow-up to obtain information on the following: 
patient and tumor characteristics, American Society of 
Anesthesiologists score, type and date of imaging, bi-
opsy, cytology and histopathology, date and outcome 
of the multidisciplinary tumor board meeting, type 
and starting date of treatment, date of last follow-up, 
and outcome. In addition, because our tertiary HNOC 
mainly provides clinical care on referral from secondary 
medical care centers, information on imaging, biopsy, 
cytology, and histopathology previously performed by 
the referring clinics.
Costs for imaging and histopathology were based 
on national medical guidelines and data from the Dutch 
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Health Authority. Costs for the initial multidisciplinary 
consultation and human papillomavirus analysis were 
not included in either group. More detailed information 
about the costs can be found in Supporting Table 1.
We defined the specialist-to-treatment interval as 
the time interval between the first consultation at the 
multidisciplinary HNOC and the start of treatment and 
then subcategorized these intervals. First, the specialist-to- 
diagnosis interval was defined as the time interval between 
the first consultation at the multidisciplinary HNOC and 
the final diagnosis, which was defined as the final Union for 
International Cancer Control classification based on the 
full and recent diagnostic workup at the multidisciplinary 
tumor board meeting. Second, the diagnosis-to-treatment 
interval was defined as the time interval between the final 
diagnosis and the start of treatment (ie, the date of surgery 
or the date of the first fraction of (chemo)radiotherapy).
Patient satisfaction was determined by means of the 
Consumer Quality (CQ) Index for Oncological Care de-
veloped by the Netherlands Institute for Health Services 
Research.15 The CQ Index was measured prospectively in 
a random cohort of patients meeting our inclusion criteria 
for CW (2009-2010) and OW (July 2013 to July 2016). 
The execution was performed by an independent third 
party. The questionnaire was sent in 2011 (CW) and in 
2015 and 2017 (OW) to a random selection of patients at 
least 18 years old with stage I to III disease.
Outcome Measurements
The endpoints of the study were as follows: time intervals 
from the first consultation to diagnosis and start of treat-
ment, number of medical imaging and pathological inves-
tigations, costs, oncological outcomes, effect of delays on 
oncological outcomes, and patient satisfaction.
For follow-up, recurrence rates, and disease-specific 
survival, we used the last outpatient checkup by the con-
sultant head and neck surgeon or radiation oncologist. 
For overall survival, we used the date of last contact or the 
date of death.
Statistical Analysis
We used SPSS version 22 for statistical analyses. A Student 
t test was used to analyze differences in continuous vari-
ables between the 2 groups, and a Mann-Whitney test was 
used in case of nonnormal distributions. A chi-square test 
was used to analyze the difference in the distributions of 
the categorical variables between the 2 groups. Pearson’s 
correlation coefficient was used to analyze the relation-
ship between variables. A Spearman correlation test was 
performed to analyze the correlation of variables that were 
TABLE 1. Optimized Workup in the Fast-Track, Multidisciplinary, Integrated Care Program
Conventional Workup (2009) Optimized Workup: Fast-Track, Multidisciplinary, Integrated Care Program (2014)
• Separate evaluations by a consultant ENT/HN 
surgeon, a consultant maxillofacial/HN surgeon, 
and a consultant HN radiation oncologista
• Imaging on the same day as the multidisciplinary 
tumor board meeting, occasionally a week later in 
case of insufficient capacity
• Staging of oropharyngeal, hypopharyngeal, and 
laryngeal tumors, including rigid laryngopharyngo-
scopy and biopsy under general anesthesia
Day 1 (first consultation):b
• Joint consultation by a consultant ENT/HN surgeon, a consultant maxillofacial/HN surgeon, 
and a consultant HN radiation oncologist
• Transnasal digital video endoscopy and office-based biopsy of laryngopharyngeal lesionsc
• Chest radiography (if no other diagnostic imaging on day 2)
• Consultation and screening by an HN oncology nurse, a dietician, a speech and swallow 
therapist, a dentist, and a dental hygienist
Day 2:
• CT (if no FDG PET-CT with diagnostic CT on day 3)
• MRI
• Ultrasonography and FNAC with direct assessment of adequacyd
• Chest radiography
• Preoperative consultation by an anesthesiologist when surgical treatment expected
• Screening by a geriatric physician if the patient is frail and older than 70 year and screening 
for younger patients with high comorbidity
Day 3:
• FDG PET-CT with diagnostic CT
• Completing reports on cytology, histopathology, and imaging
• Discussing and establishing a treatment plan at the multidisciplinary tumor board meeting
Abbreviations: CT, computed tomography; ENT, ear, nose, and throat; FDG, [18F]fluorodeoxyglucose; FNAC, fine-needle aspiration cytology; HN, head and neck; 
MRI, magnetic resonance imaging; PET, positron emission tomography.
aFirst consultation within 1 week. These visits did not routinely take place on the same day.
bGuaranteed access to the multidisciplinary Head and Neck Oncology Center within 1 week.
cUnless there was an indication for a procedure under general anesthesia for other reasons (eg, tonsillectomy, tracheotomy, or transoral laser microsurgery). Routine 
rigid laryngopharyngoscopy and biopsy under general anesthesia were no longer performed.
dGenerally, up to 2 nodes were punctured per side of the neck (1 suspected node in the area of primary drainage and the most caudal suspected node). The 
cytology specimen was immediately checked for cellular content, and when this was reported to be inadequate, repeat aspiration was performed in the same 
examination.
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not normally distributed. Overall survival was analyzed 
with a Kaplan-Meier curve and a log-rank test. A multi-
variable Cox proportional hazards regression analysis was 
performed to correct for confounding factors between the 
studied groups for overall survival. Proportional hazards 
assumptions were tested. For the risk of recurrence and 
death due to disease, the crude cumulative incidence was 
calculated, and competing risk analyses were performed 
in Strata/SE 11.2. CW was set as 1, and OW was set as 0. 
A P value less than .05 was considered significant.
RESULTS
Patients
During the study period, 394 and 457 patients presented 
at our HNOC in 2009 and 2014, respectively. A total of 
218 patients were eligible for inclusion in the CW cohort 
(2009), and 268 were eligible for the OW cohort (2014). 
Figure 1 presents a flowchart of inclusion and reasons for 
exclusion. Table 2 presents the baseline characteristics and 
treatment details. A significant difference between the 
groups was found for age, with patients in the OW group 
being on average 2 years older (P = .012). Furthermore, 
there were significantly more patients at stage T1 
(P = .028) and stage N0 (P = .037) in the OW cohort, 
and this resulted in significantly fewer patients with stage 
III to IV disease in this cohort (P = .033).
Time to Diagnosis and Treatment Interval
The median specialist-to-diagnosis interval was 9.0 and 
2.0  days for CW and OW, respectively. The median 
diagnosis-to-treatment interval was 25.0 and 18.0 days, 
respectively. The median specialist-to-treatment interval 
was 34 days for CW (range, 2-83 days) and 21 days for 
OW (range, 2-99 days). All intervals were significantly 
shorter in the OW group (see Table 3 and Supporting 
Fig. 1). We did not find a relevant correlation (r > 0.200) 
between tumor site and specialist-to-treatment interval. 
Overall, the specialist-to-treatment interval was within 
30 days in 46% (CW) and in 80% (OW).
Figure 1. Flowchart. *Suspected malignant tumors with diagnostic and (surgical) therapeutic workup as malignant tumors were 
included. HNC indicates head and neck cancer.
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Number of Medical Examinations
Comparing 2009 with 2014, we found a significant 
increase in the number of patients who underwent chest 
radiography and ultrasonography with FNAC at the re-
ferring clinics, although the absolute numbers remained 
relatively low. Significantly fewer patients had histopatho-
logical examinations at the referring clinics. We found a 
significant increase in the number of PET-CT scans in 
the OW group versus the CW group at our HNOC. 
The total number of ultrasonographs remained the same, 
but significantly more ultrasonographs with FNAC were 
performed in 2014. Rigid endoscopy was performed sig-
nificantly less frequently and flexible endoscopic biopsy 
was performed significantly more frequently in the OW 
group than the CW group (P  =  .009 and P  <  .0001, 
respectively). The results are summarized in Supporting 
Tables 2 and 3.
Diagnostic Costs
The mean absolute costs for imaging, pathology, and 
endoscopy in the referring clinics were comparable in 
the 2 groups (Supporting Table 4). At our HNOC, there 
was a significant increase in pathology costs over time, 
but average costs per patient for endoscopy decreased 
from €703 in 2009 to €452 in 2014 (P < .0001). The 
total diagnostic costs of the referring clinic and our 
HNOC combined did not show a significant difference 
between CW and OW. The results are summarized in 
Supporting Table 4.
Oncological Outcomes
The mean follow-up was 49 and 29 months in the CW 
and OW groups, respectively. The OW group showed 
significantly better overall survival. The 3-year overall sur-
vival rate was 72% in the CW group and 84% in the OW 
group (P = .002; Fig. 2); 58 and 37 patients, respectively, 
died during this period. After correction for confounders 
(Table 4), the 3-year risk of death was significantly higher 
for patients in 2009 than for patients in 2014 (hazard ratio 
[HR], 1.73; 95% confidence interval [CI], 1.14-2.63; 
P = .010). The 3-year disease-specific survival rate was 82% 
in the CW group and 88% in the OW group (P = .056). 
After correction for confounders, a competing risk analysis 
showed that death due to disease was not different in the 
2 groups (subdistribution hazard ratio [SHR], 1.33; 95% 
CI, 0.80-2.22; P = .272). The 3-year crude cumulative in-
cidence for recurrent disease was not significantly different 
(SHR, 1.18; 95% CI, 0.83-1.67; P = .361).
The proportional hazards assumptions were met 
(P = .570).
Effect of an Increased Interval to the Start  
of Treatment on Oncological Outcomes
Overall, patients with a specialist-to-treatment interval 
longer than 30 days had a 5-year overall survival rate of 
58%, whereas patients with an interval of 30  days or 
less had a 5-year overall survival rate of 78% (P = .003; 
Fig. 3). After correction for the covariates mentioned in 







Sex, No. (%) .297a
Male 156 (71.6) 180 (67.2)
Female 62 (28.4) 88 (32.8)
Age, mean (SD), y 62.7 (10.6) 64.8 (11.8) .012b
ASA score, No. (%) .738a
1 41 (18.8) 52 (19.4)
2 132 (60.6) 161 (60.1)
3 44 (20.2) 55 (20.5)
4 1 (0.5) 0
Tumor site, No. (%) .473a
Lip 7 (3.2) 4 (1.5)
Oral cavity 53 (24.3) 82 (30.6)
Oropharynxc 45 (22.6) 39 (14.6)
Hypopharynx 13 (6.0) 14 (5.2)
Larynx 60 (27.5) 83 (31.0)
Nose/paranasal 
sinuses
14 (6.4) 19 (7.1)
Nasopharynx 8 (3.7) 5 (1.9)
Salivary glands 10 (4.6) 13 (4.9)
Ear canal 2 (0.9) 1 (0.4)
Nodal metastasis 6 (2.8) 8 (3.0)
T stage, No. (%)
T0 6 (2.8) 7 (2.6) .924a
Tis 8 (3.7) 8 (3.0) .674a
T1 54 (24.8) 91 (34.0) .028a
T2 72 (33.0) 77 (28.7) .307a
T3 35 (16.1) 43 (16.0) .998a
T4 40 (18.3) 38 (14.2) .213a
Benign 3 (1.4) 4 (1.5) .915a
N stage, No. (%)
N0 132 (60.6) 186 (69.4) .037a
N1 25 (11.5) 18 (6.7) .067a
N2 55 (25.2) 54 (20.1) .183a
N3 3 (1.4) 6 (2.2) .482a




0-II 93 (43.3) 140 (53.0)
III-IV 122 (56.7) 124 (47.0)
Treatment, No. (%) .643a
Surgery ± po(C)
RT
117 (53.7) 147 (54.9)
Radiotherapy 68 (31.2) 87 (32.5)
Chemoradiation 32 (14.7) 34 (12.7)
Chemotherapy 1 (0.5) 0
Abbreviations: AJCC, American Joint Committee on Cancer; ASA, American 
Society of Anesthesiologists; po(C)RT, postoperative (chemo)radiation; SD, 
standard deviation; UICC, Union for International Cancer Control.
aChi-square test.
bt test.
cNo difference in p16-positive tumors (p = .174).
dExcluding benign lesions.
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Table 4 (excluding year), overall survival was still signif-
icantly better for patients with an interval of 30 days or 
less (HR, 1.52; 95% CI, 1.06-2.17; P = .023). Disease-
specific survival was not statistically significantly influ-
enced by delay.
Patient-Reported Experience
The CQ Index was determined for 55 patients in the CW 
group and for 84 patients in the OW group. The overall 
evaluation of satisfaction with care (on a scale of 0-10, 
with 10 being the highest score) was 8.51 for CW patients 
and 9.05 for OW patients (P = .007).
DISCUSSION
This study reports on outcomes before and after the 
implementation of a fast-track, multidisciplinary, integrated 
TABLE 3. Medians, Means, SDs, and P Values for the Intervals in Days
Interval
Conventional Workup (2009), 
Median/Mean (SD)
Optimized Workup (2014), 
Median/Mean (SD) Pa
Specialist to diagnosis 9.0/10.0 (8.9)b 2.0/6.2 (9.4)c <.0001
Diagnosis to treatment 25.0/24.7 (11.8)b 18.0/18.5 (8.1)c <.0001
Specialist to treatment 34.0/33.4 (14.5)d 21.0/24.4 (12.8)e <.0001






Figure 2. Kaplan-Meier curves of overall survival. Overall survival was analyzed after the exclusion of 4 patients in the conventional 
workup group and 3 patients in the optimized workup group due to benign lesions instead of malignant lesions.
TABLE 4. Multivariable Cox Regression Analysis for 
Overall Survival
Variable Hazard Ratio 95% CI P
Year (1 = 2009; 0 = 2014) 1.734 1.141-2.634 .010a
Sex (1 = male; 0 = female) 1.056 0.669-1.666 .815
Age 1.021 1.001-1.043 .043a
ASA score (1 = 2-4; 0 = 1) 1.658 0.867-3.172 .127






Site: Tis/1 glottic 0.166 0.022-1.252 .082
Site: lip 0.623 0.083-4.698 .646
Site: oropharynx 1.436 0.838-2.462 .188
Site: ear 5.125 1.211-21.687 .026a
Site: hypopharynx 1.777 0.896-3.524 .100
HPV p16+ 0.188 0.043-0.817 .026a
Abbreviations: AJCC, American Joint Committee on Cancer; ASA, American 
Society of Anesthesiologists; CI, confidence interval; HPV, human papilloma-
virus; UICC, Union for International Cancer Control.
aP < .05.
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care program at our HNOC. The main interventions 
included a 1-day combined consultation with consult-
ant head and neck surgeons, consultant radiation on-
cologists, and allied health professionals at 1 clinic; the 
introduction of transnasal digital video endoscopy with 
office-based biopsy (OBB); fast and efficient planning of 
medical imaging; and swift cytological and histopatho-
logical assessment. This resulted in a significant decrease 
in the median specialist-to-treatment interval from 34 to 
21 days. Three-year overall survival and overall satisfac-
tion with care were significantly higher in the OW group 
than the CW group. The diagnostic costs did not differ 
between the 2 cohorts.
One of the interventions introduced to reduce diag-
nostic intervals was digital video endoscopy with OBB, 
which obviates the need for endoscopy and biopsy as well 
as general anesthesia with its associated risks, consulta-
tions, and operating room planning issues. OBB is well 
tolerated and safe.16-21 Studies have shown that when 
the histological outcome of OBB has been invasive squa-
mous cell carcinoma, the diagnosis has been confirmed in 
100% of the cases with a final histological diagnosis using 
operative biopsies.21-23
Median specialist-to-diagnosis and special-
ist-to-treatment intervals were significantly decreased 
from 9 to 2 days and from 34 to 21 days, respectively. 
The 2018 annual report by the Dutch Head and Neck 
Audit describes the median time intervals of all Dutch 
HNC centers combined, including our center. It found 
a median specialist-to-diagnosis interval of 13 days and 
a specialist-to-treatment interval of 30  days for 2015-
2017.24 The diagnosis-to-treatment interval at our HNC 
center was significantly decreased from 25 to 18  days. 
This interval from the final diagnosis to the start of treat-
ment varies widely in the literature. Two large studies, 
including 13,140 and 51,655 patients with HNC in the 
Netherlands and the United States, found median diag-
nosis-to-treatment intervals of 37 and 26  days, respec-
tively.2,10 However, they defined the date of diagnosis as 
the date of the cytological or histological diagnosis and 
the date of the pathology report, respectively,2,10 and not 
necessarily as the date of the final diagnosis and establish-
ment of the treatment plan at a tumor board meeting, as 
in our study.
The introduction of our fast-track, multidisciplinary, 
integrated care program with OW was cost-effective and 
did not lead to an increase in total costs. The average cost 
per patient for all those who underwent endoscopy (rigid 
and/or flexible) at the HNOC decreased significantly be-
cause of the introduction of OBB. Naidu et al23 and Fang 
et al25 also reported significantly lowered costs with flex-
ible endoscopic biopsy in comparison with biopsy under 
general anesthesia. Simons et al26 redesigned their care 
processes by introducing OBB and performing PET-CT 
Figure 3. Kaplan-Meier curves of specialist-to-treatment interval and overall survival. Overall survival was analyzed after the 
exclusion of 7 patients due to benign lesions instead of malignant lesions.
Optimizing Head and Neck Cancer Workup/Schutte et al
3989Cancer  September 1, 2020
in radiotherapy position and found that their redesign 
proved to be cost-effective and led to reduced waiting 
times. Diagnostic costs are, however, just a fraction of the 
costs of treatment.27 Although we did not study this in 
our cohorts, it is likely that disease progression caused by 
prolonged diagnostic and therapeutic intervals will result 
in a higher number of cases that need additional treat-
ment or even revision of the treatment plan in some cases.
We found a 12% increase in 3-year overall survival 
between 2009 and 2014, and it remained significantly 
higher after correction for confounders, especially includ-
ing stage. Multivariable Cox proportional hazards analy-
ses showed a 1.73 higher risk of death for the CW group 
compared with the OW group at the 3-year follow-up. 
Multivariable competing risk analyses of death due to 
HNC and recurrence rates also seemed in favor of OW, 
but the differences did not reach statistical significance. 
The nonsignificant adjusted HR of death due to HNC of 
1.33 in the CW group versus the OW group may be ex-
plained by several changes. Tumor staging and subsequent 
treatment might be more adequate because of more up-
to-date imaging and the constantly increasing accuracy of 
medical imaging, including the increased use of PET-CT. 
Furthermore, there was an increased use of postoperative 
chemoradiation in patients in 2014, but this concerned 
only 0.9% and 4.9% of the patients in the CW and OW 
groups, respectively. These differences had only a minor 
impact on overall outcomes in the studied population. 
In addition to reduced time-to-treatment intervals, the 
systematic integration of upfront geriatric assessment for 
elderly patients and screening by dentists, dental hygien-
ists, dieticians, and speech and swallow therapists also 
contributes to the improvement of quality of care and is 
also likely to have played a role in determining survival 
outcomes.
We found that a specialist-to-treatment interval lon-
ger than 30  days negatively influenced overall survival, 
even after adjustments for comorbidity, stage, and age, 
among others (HR, 1.52; 95% CI, 1.06-2.17; P = .023). 
Two recent large studies by Murphy et al2 and van Harten 
et al10 studied the influence of the diagnosis-to-treatment 
interval on overall survival. Murphy et al found that the 
overall survival for patients treated with a curative intent 
was significantly lower if the interval between diagnosis 
and treatment was 61 days or longer in comparison with 
an interval of 30  days or less. Van Harten et al found 
significantly lower overall survival with longer intervals 
when the cutoff was set at 37 days (median) but not with 
a cutoff at 30 days. Van Harten et al, however, did not 
adjust for comorbidity.
We used the CQ Index to assess patients’ experiences 
and found that overall satisfaction with care was high in 
both groups and significantly higher in the OW group. 
This may be due to improved quality of care and the 
faster diagnostic path. The literature provides insufficient 
data on patient-reported outcome measures and delays in 
HNC. International comparisons would in any case be 
difficult to make because of societal or cultural differences 
and differences in the case mix.
An important limitation is the retrospective nature 
of our study. Complex cases requiring dedicated imaging, 
additional consultation, and diagnostic procedures for (in-
cidental) findings (eg, pulmonary nodules on chest CT or 
nonphysiological intestinal [18F]fluorodeoxyglucose uptake 
on PET) will have prolonged time-to-treatment intervals. 
Although we did correct for stage and comorbidity, it re-
mains unclear whether these factors still affected overall 
survival, especially in patients with a specialist-to-treatment 
delay longer than 30 days.
The most important difference in the patient char-
acteristics between our studied cohorts was the higher 
number of patients with stage 0 to II disease in the OW 
group. In this group, we found more T1 carcinoma of 
the nose/paranasal sinuses (P = .006) and more N0 oral 
cavity cancer (P = .039). Analyzing our data separately 
for stage 0 to II and stage III to IV tumors, we found that 
specialist-to-diagnosis, diagnosis-to-treatment, and spe-
cialist-to-treatment intervals remained statistically sig-
nificant in favor of the OW cohort, and total diagnostic 
costs were still comparable. The differences in baseline 
characteristics may be explained by increased awareness 
for HNC and earlier referral by general practitioners, 
dentists, and/or referring consultants. In addition to the 
implementation of a fast-track, multidisciplinary, inte-
grated care program, we actively encouraged referring 
specialists to refer patients with suspected HNC with-
out imaging and histopathology to avoid unnecessary 
delays before oncological workup at our HNC center. 
There were no major alterations in treatment protocols 
between the investigated cohorts. As mentioned previ-
ously, there was increased use of postoperative chemo-
radiation in patients in 2014. Furthermore, peer review 
of radiotherapy target volume contouring has been in-
troduced. In addition, reirradiation has become more 
accepted for recurrences and second primary tumors.28 
Lastly, the evolution of chemotherapy agents, targeted 
therapies, and immunotherapy after the development 
of an incurable recurrence or distant metastasis may in-
crease overall survival. However, in the studied cohorts, 
there were no significant differences in these treatments 
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or reirradiation for recurrent disease, distant metastasis, 
or second primary tumors.
In conclusion, after the implementation of a fast-
track, multidisciplinary, integrated care program, the in-
terval from the first consultation to the start of treatment 
was considerably shortened, overall survival significantly 
improved, patient satisfaction increased, and costs re-
mained the same. In addition, the detrimental effects on 
survival of progression of disease due to prolonged time-
to-treatment intervals may be compensated by intensified 
or adjuvant treatment. Optimizing the diagnostic track 
and quality of care results in better oncological outcomes 
without increases in toxicity or costs.
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